Incyte Corporation (BIT:1INCY)

Market Cap	16.52B
Revenue (ttm)	4.10B
Net Income (ttm)	1.01B
Shares Out	n/a
EPS (ttm)	5.03
PE Ratio	16.30
Forward PE	11.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	22
Open	n/a
Previous Close	83.68
Day's Range	n/a
52-Week Range	47.33 - 94.30
Beta	n/a
RSI	45.82
Earnings Date	Feb 3, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD